Black checkmark with a sparkle and a curved line underneath on a white background.
Company

INTEGRATED BIOPHARMA INC

Ticker
INBP
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and sector-related updates with no direct company-specific operational announcements.

Recent developments:
  • No company-specific recent developments were reported in the latest news cycle; coverage primarily relates to broader market and sector conditions [N1][N2][N3][N4][N5][N6][N7][N8].
Overview

Integrated BioPharma Inc operates primarily in the nutraceutical and dietary supplement manufacturing sector. The company’s business model relies heavily on contract manufacturing for major customers such as Life Extension and Herbalife. It sources raw materials including vitamins, minerals, herbs, and packaging components from multiple suppliers domestically and internationally, generally on a purchase order basis without long-term contracts. The company faces regulatory oversight from multiple U.S. federal agencies and must comply with evolving standards that can affect product formulation, labeling, and marketing. Its stock is quoted on the OTCQX Best Market, subject to ongoing compliance requirements.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Integrated BioPharma Inc is a nutraceutical manufacturer with significant customer concentration and regulatory exposure. The company reported a net loss of $691,000 for the quarter ended September 30, 2026, with liquidity ratios indicating a current ratio of 2.93 and cash ratio of 0.57 as of that date. Risk factors include supply chain disruptions, regulatory compliance costs, cybersecurity threats, and concentrated ownership control [S1][S2].

Scenarios for INBP

Bull case model:

The company’s established customer base and contract manufacturing relationships provide a stable revenue foundation. Its compliance with stringent regulatory requirements and investment in IT infrastructure may support operational resilience. The liquidity position with a current ratio near 3 suggests capacity to manage short-term obligations. Continued management leadership and control by experienced executives may facilitate strategic execution.

Bear case model:

Significant customer concentration exposes the company to revenue volatility if key customers are lost. Supply chain disruptions and rising costs from geopolitical events and inflation pressure margins. Regulatory changes could increase compliance costs or restrict product offerings. Cybersecurity threats and reliance on third-party cloud providers pose operational risks. Concentrated ownership and related-party transactions may present governance challenges. Product liability exposure and limited insurance coverage add financial risk.

Moat:

Integrated BioPharma’s moat is primarily based on its established relationships with major customers in the contract manufacturing segment and its regulatory compliance capabilities in a highly regulated nutraceutical industry. The company’s operational infrastructure, including enterprise resource planning and IT systems, supports its manufacturing and supply chain processes. However, the high customer concentration and regulatory risks limit the breadth of its competitive advantage.

Risks overview
Risks summary
The company’s significant customer concentration combined with regulatory and supply chain risks represent the most material threats to its business stability and financial performance.
Risks details:

• Customer Concentration Risk: Approximately 90% of consolidated net sales in fiscal 2026 were derived from two major customers, creating significant revenue dependency.
• Supply Chain and Cost Pressures: Geopolitical events and inflation have caused supply chain disruptions and increased costs for raw materials, fuel, and labor, negatively impacting margins.
• Regulatory Compliance Risk: The company is subject to extensive regulation by multiple agencies; changes or enforcement actions could increase costs or restrict product sales.
• Cybersecurity and IT Risks: Dependence on IT systems and third-party cloud providers exposes the company to cyber threats and operational disruptions.
• Ownership and Governance Risks: Majority ownership by executives and directors may lead to conflicts of interest and limit influence of other shareholders.
• Product Liability Exposure: The company maintains product liability insurance which may be insufficient to cover potential claims related to its nutraceutical products.

FINAL FORECAST FOR INBP

Final take one line
Integrated BioPharma Inc exhibits very high visibility with detailed regulatory, operational, and financial disclosures highlighting concentrated customer risk and regulatory compliance as key considerations.
Final take 12 to 24 month view

Business trends: Continued reliance on major customers in contract manufacturing and exposure to regulatory and supply chain pressures.
Execution milestones: Maintaining regulatory compliance, managing supply chain disruptions, and sustaining liquidity ratios.
Key risks: Customer concentration, regulatory changes, supply chain volatility, cybersecurity threats, and governance concentration.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Integrated BioPharma Inc operates in the nutraceutical and dietary supplement manufacturing industry.
  • The company derives a significant portion of its revenue from a few major customers, notably Life Extension, Herbalife, and Life Tech, with approximately 90% of consolidated net sales in fiscal 2026 from two major customers in the Contract Manufacturing Segment.
  • The company faces risks related to supply chain disruptions due to geopolitical events and rising costs such as fuel and labor, impacting margins.
  • Integrated BioPharma is subject to extensive regulation by multiple U.S. federal agencies including the FDA, FTC, Consumer Product Safety Commission, Department of Agriculture, and EPA, as well as state and international regulations.
  • Government regulations may delay product introductions, require reformulations, or cause product removals, which could increase costs and reduce revenues.
  • The company is exposed to legal proceedings from regulators or third parties that could increase costs and affect reputation and financial results.
  • Key executives include Co-Chief Executive Officers Christina Kay and Riva Sheppard, and Chief Financial Officer Dina L. Masi; the company depends heavily on their leadership.
  • The company maintains enterprise resource planning and IT systems critical to operations and faces cybersecurity risks including AI-driven threats and reliance on third-party cloud providers such as Microsoft Azure.
  • Climate change and natural disasters pose risks to supply chain, production capabilities, and costs due to energy and raw material impacts.
  • The company’s common stock is quoted on the OTCQX Best Market since January 22, 2021, with requirements for continued compliance.
  • There are related-party transactions involving entities controlled by officers and directors, which may pose conflicts of interest.
  • Executive officers, directors, and a significant stockholder collectively own approximately 72% of outstanding shares, concentrating control.
  • The Board of Directors is staggered into three classes with three-year terms, potentially impeding changes in control or management.
  • Product liability insurance coverage is $5 million per occurrence and aggregate, which may be insufficient for potential claims.
  • Raw materials for nutraceutical products include vitamins, minerals, herbs, fruit extracts, capsules, and packaging materials sourced from multiple suppliers domestically and abroad.
  • The company purchases raw materials mostly on a purchase order basis without long-term commitments, exposing it to sourcing risks.
  • Economic conditions in North America affect the company’s operating results, including credit availability, market volatility, tariffs, and labor market conditions.
  • The company incurs costs to comply with regulatory requirements, which may increase and affect competitiveness.
  • Financial snapshot as of September 30, 2026: cash and equivalents $3.12 million, current assets $15.98 million, current liabilities $5.45 million, current ratio 2.93, cash ratio 0.57.
  • Net income for the quarter ended September 30, 2026 was a loss of $691,000, with basic and diluted EPS of -$0.02.
  • Revenue figure available from 2018 Q1 was $10.3 million, but no recent revenue figures disclosed in the latest filings.
  • No material changes to risk factors were reported in the latest 10-Q compared to the 10-K for fiscal year ended June 30, 2026.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-09-25 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Teekay Tankers (TNK) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/teekay-tankers-tnk-q3-2026-earnings-call-transcript
  • N2 | 2026-11-13 | www.nasdaq.com | Stocks Pressured by Rising Bond Yields | https://www.nasdaq.com/articles/stocks-pressured-rising-bond-yields-2
  • N3 | 2026-11-13 | www.nasdaq.com | Wheat Taking Back Some of Thursday’s Losses on Friday Morning | https://www.nasdaq.com/articles/wheat-taking-back-some-thursdays-losses-friday-morning
  • N4 | 2026-11-13 | www.nasdaq.com | Stocks Settle Lower on Nvidia Rout and Higher Crude and Bond Yields | https://www.nasdaq.com/articles/stocks-settle-lower-nvidia-rout-and-higher-crude-and-bond-yields
  • N5 | 2026-11-13 | www.nasdaq.com | Corn Starting Friday with Modest Gains | https://www.nasdaq.com/articles/corn-starting-friday-modest-gains
  • N6 | 2026-11-13 | www.nasdaq.com | Turning 62 in 2027? These 3 Social Security Rules Might Surprise You. | https://www.nasdaq.com/articles/turning-62-2027-these-3-social-security-rules-might-surprise-you
  • N7 | 2026-11-13 | www.nasdaq.com | SKYX Platforms (SKYX) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/skyx-platforms-skyx-q3-2026-earnings-call-transcript
  • N8 | 2026-11-13 | www.nasdaq.com | Aeluma (ALMU) Q1 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/aeluma-almu-q1-2027-earnings-call-transcript
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine